How Patients Respond to Genetic Testing for AMD—And Why It Matters

When it comes to age-related macular degeneration (AMD)—the leading cause of blindness in older adults—knowledge is power. While aging is inevitable, proactive steps can significantly reduce the risk of vision loss. One of the most promising tools for prevention is genetic testing for AMD.

A recent study, How Do Patients Respond to Genetic Testing for Age-related Macular Degeneration?, explored how patients respond when offered genetic testing for AMD. The findings highlight why genetic insights, combined with preventive care, can reshape the future of eye health.

Patient Responses to AMD Genetic Testing

  • Strong demand for testing: Nearly 85% of patients invited to participate chose to undergo genetic testing. Many were motivated by a family history of AMD or other eye diseases.
  • Lifestyle and behavior changes: Even patients with low genetic risk reported making proactive changes—such as wearing sunglasses, quitting smoking, or taking supplements—after receiving results.
  • Empowerment through knowledge: More than 60% said they would be interested in additional genetic testing for other diseases, emphasizing that “knowledge is power”.

This confirms that AMD genetic testing doesn’t just predict risk—it drives action.

How Visible Genomics Supports Proactive Eye Care

At Visible Genomics, we specialize in genetic testing for AMD that empowers both patients and eye care professionals. Our AMDiGuard™ test provides personalized insight into genetic risk factors—long before vision changes occur.

The study results align with our mission: when patients understand their genetic risk, they are more likely to take proactive eye health measures that may preserve vision for years to come.

Take Control of Your Eye Health

Genetic testing for AMD is not about predicting the future—it’s about preparing for it with confidence. By combining genetic insights with protective lifestyle changes, patients can shift from reactive treatment to proactive prevention.

At Visible Genomics, we believe earlier knowledge leads to better outcomes. That’s why we’re committed to advancing tools like AMDiGuard™ to help preserve sight and independence.